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Abstract
Background: Vitiligo is a common skin disorder, characterized by progressive skin de-pigmentation due to the loss of
cutaneous melanocytes. The exact cause of melanocyte loss remains unclear, but a large number of observations have
pointed to the important role of cellular immunity in vitiligo pathogenesis.
Methodology/Principal Findings: In this study, we characterized T cell and inflammation-related dermal dendritic cell (DC)
subsets in pigmented non-lesional, leading edge and depigmented lesional vitiligo skin. By immunohistochemistry staining,
we observed enhanced populations of CD11c+ myeloid dermal DCs and CD207+ Langerhans cells in leading edge vitiligo
biopsies. DC-LAMP+ and CD1c+ sub-populations of dermal DCs expanded significantly in leading edge and lesional vitiligo
skin. We also detected elevated tissue mRNA levels of IL-17A in leading edge skin biopsies of vitiligo patients, as well as IL-
17A positive T cells by immunohistochemistry and immunofluorescence. Langerhans cells with activated inflammasomes
were also noted in lesional vitiligo skin, along with increased IL-1ß mRNA, which suggest the potential of Langerhans cells to
drive Th17 activation in vitiligo.
Conclusions/Significance: These studies provided direct tissue evidence that implicates active Th17 cells in vitiligo skin
lesions. We characterized new cellular immune elements, in the active margins of vitiligo lesions (e.g. populations of
epidermal and dermal dendritic cells subsets), which could potentially drive the inflammatory responses.
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Introduction
Vitiligo is a common skin disorder, affecting over 0.5% of the
world population [1]. It is characterized by progressive skin de-
pigmentation due to the loss of cutaneous melanocytes and
abnormal melanocyte function. There are two types of vitiligo:
segmental and non-segmental. Non-segmental vitiligo occurs at
sites sensitive to pressure or friction, and it accounts for up to 90%
of cases overall [2]. The exact cause of melanocyte loss in non-
segmental vitiligo is still debatable, but many observations have
pointed to the important role of cellular immunity in its disease
pathogenesis. [3,4,5,6].
Earlier studies have shown that depigmenting vitiligo skin is
accompanied by lymphocytic infiltrates containing both CD4+
and CD8+ T cells at the dermal-epidermal junction. The skin-
infiltrating cytotoxic T cells were found to be juxtaposed with
melanocytes and were enriched for melanocyte antigen recogni-
tion [7,8]. T cells isolated from peri-lesional skin of vitiligo patients
also showed cytotoxicity against autologous melanocytes in vitro
[9]. The onset of vitiligo seen following immunotherapy of
melanoma using infusion of Melan-A specific CD8+ T-cell clones
or dendritic cell vaccines provide additional support for the
autoimmune hypothesis of vitiligo pathogenesis [10,11].
Like in many other inflammatory diseases, the pathogenesis of
vitiligo includes an active population of T-helper 1 cells [12,13],
and the treatment of vitiligo using IFN-c inhibition has given
positive responses [14]. Although Th17 polarization is another
important arm in the progression of inflammatory diseases
including psoriasis [15,16,17] [18,19], there have been very
limited data on whether Th17 cells participate in the pathogenesis
of vitiligo [20].
In this study, we aimed to characterize the Th1 and Th17
components in vitiligo, as well as the epidermal Langerhans cell
and myeloid dermal dendritic cell populations, which are capable
of driving the proliferation of T cells by presenting autoantigens
and producing inflammatory cytokines [19,21]. It has been
demonstrated that Langerhans cells and myeloid dermal dendritic
cells can stimulate T cells to directly expand Th1, Th2 and Th17
responses [22,23,24,25]. Hence, one can take the view that
autoinflammatory or autoimmune responses in the skin can be
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18907driven by factors that, in focal skin regions, will activate DCs,
which might then activate specific T cell populations in the skin.
Results
Loss of melanocytes in lesional and leading edge vitiligo
skin
Vitiligo is characterized by the loss of melanocytes and the
resulting absence of melanin from the epidermis [2]. Here, we
labeled Melan-A, a melanocyte marker, to quantify melanocytes in
normal appearing non-lesional skin, depigmented lesional skin and
the leading edge skin from vitiligo patients. Melan-A is a
melanosomal protein that can be recognized by autologous
cytotoxic T lymphocytes [26,27,28]. In Fig. 1B, immunohisto-
chemical staining of Melan-A showed abundant expression in
pigmented non-lesional skin. Melanized keratinocytes and mela-
nocytes were found at the dermal-epidermal junction. By
comparison, staining of the leading edge of depigmented vitiligo
skin showed fewer Melan-A positive cells (p,0.0956). In
depigmented lesional skin samples, melanocytes were absent and
no positivity was found (p,0.0082). The staining pattern of
Melan-A shown in Fig. 1B coincides with the degree of
depigmentation in our vitiligo biopsies.
T cell infiltration at lesional and leading edge vitiligo skin
Previous reports of T cell infiltration accompanying vitiligo
progression have suggested T cell mediated cytotoxicity as a
mechanism for melanocyte killing [29,30]. As expected, significant
CD3+ and CD8+ T cell infiltration was observed in vitiligo skin,
and clusters of T cells were identified near the disappearing
melanocytes at dermal-epidermal junctions (Fig. 1C&D). These T
cells predominately infiltrated to the leading edge of depigmented
skin, where progressive loss of skin pigmentation and destruction
of melanocytes were taking place. CD3+ T cells were localized
primarily in the papillary and upper reticular dermis of the leading
edge of vitiligo lesions and were often organized as aggregates
(Fig. 1C). Another major distinction between leading edge vitiligo
skin and non-lesional skin is that T cells were frequently observed
to be in direct contact with the basal epidermis or infiltrating the
epidermis in the former. Double fluorescence stainings of CD3/
CD4 and CD3/CD8 are included as Figure S1&S2. In the skin, a
majority of CD3+ cells are also CD4+ (.60%). CD32/CD4+
population will include dermal dendritic cells; CD3+/CD42 cells
are also detected, indicating a mixed CD4+ and CD8+ T cell
infiltrate in vitiligo.
Analysis of DC subsets in vitiligo skin
Langerhans cells were quantified by CD207/Langerin staining
(Fig. 2A). Quantitative image analysis by cell counting showed that
compared to non-lesional skin, the leading edge contained higher
numbers of epidermal Langerhans cells (p,0.0339). In leading
edge and lesional biopsies, Langerhans cells tended to reside in the
lower half of the epidermis. However, in the uninvolved skin of
these patients, Langerhans cells were more uniformly distributed
in the stratum malpighii of the epidermis, which is more similar to
their distribution pattern in normal skin of healthy individuals.
We used integrin CD11c as a general marker for quantifying
dermal dendritic cell populations across non-lesional, lesional, and
leading edge vitiligo skin biopsies. In normal skin, CD11c+ DCs
are found in the papillary and upper reticular dermis, but direct
contact with basal keratinocytes is not apparent [19]. In contrast,
in vitiligo biopsies, CD11c+ myeloid DCs preferentially localized
to the dermal-epidermal junction, often forming aggregates
(Fig. 2B). In leading edge and lesional biopsies, CD11c+ DCs
were frequently juxtaposed with basal keratinocytes/melanocytes,
and some invasion of CD11c+ DCs into the basal epidermis was
apparent. Leading edge biopsies contained significantly larger
numbers of CD11c+ DCs than pigmented non-lesional (p,0.0183)
and also lesional samples. Additionally, larger numbers of CD11c+
DCs were found in lesional skin than pigmented non-lesional
vitiligo skin (p,0.0184).
One subset of CD11c+ dermal DCs is the CD1c/BDCA-1+
resident dermal DCs [23]. In normal skin, these CD11c+ CD1c+
cells are relatively immature with modest T-cell stimulatory ability.
Here, the CD11c+ CD1c+ dendritic cells were found throughout
the upper dermis of non-lesional, lesional and leading edge vitiligo
skin (Fig. 2C). Clinically pigmented skin contained the lowest
numbers of CD1c+ DCs, while leading edge biopsies showed the
highest numbers of CD1c+ DCs (p,0.0588).
CD11c also marks another subset of CD11c+/CD1c2 DCs,
which we have termed ‘‘inflammatory dermal DCs’’, or, in the
case of psoriasis, ‘‘TIP-DCs’’ (TNF and iNOS-producing DCs)
[21,31]. In this study, we saw a remarkable rise in the number of
CD11c+ DCs in the leading edge of vitiligo skin, which contained
enhanced populations of both CD1c+ and CD1c2 DCs (Fig. 2B).
This result is different from the observations we made in other
disease models, including psoriasis and squamous cell carcinoma,
where the CD11c+ CD1c+ DC population stays relatively
unchanged in number, but the CD11c+ CD1c2 DC population
shows a dramatic expansion [32].
More mature/activated Langerhans cells and dermal DCs
are found in leading edge vitiligo skin
We also stained for HLA-DR+ and DC-LAMP+ cells across the
three groups of vitiligo skin biopsies (i.e. lesional, non-lesional,
leading edge) (Fig. 2D&E). Our staining showed regular
distributions of Langerhans cells in the suprabasal layers of the
epidermis in almost all vitiligo biopsies, and the highest number of
DC-LAMP expressing cells was found in leading edge skin. The
expression of HLA-DR was higher on dendritic cells in the
epidermis, suggesting that Langerhans cells in the depigmenting
lesions are more activated compared to non-lesional skin (Fig. 2D).
Increased numbers of HLA-DR+ cells were recorded in leading
edge (p,0.0358) and lesional biopsies. Aggregates of DC-LAMP+
cells were seen at dermal-epidermal junctions in leading edge skin,
and their numbers were noticeably higher than that of non-
lesional (p,0.046) or depigmented lesional skin (Fig. 2E).
Scattered CD83+ cells with dendritic morphology were found in
the upper dermis and epidermis of vitiligo biopsies, including non-
lesional, leading edge and depigmented. Some CD83+ cells are
located in the epidermis, consistent with LC maturation It is
important to note that normal skin does not contain this CD83+
cell population. (Figure S3). For negative controls, mouse IgG1,
IgG2a and IgG2b were applied to leading edge vitiligo skin
sections at the same concentration as primary antibodies of the
same isotypes, and immunohistochemistry micrographs are shown
in Fig. 2F. Prior to performing immunohistochemistry staining on
vitiligo biopsies, all primary antibodies used in Fig. 2 were tested
on psoriasis lesional and non-lesional skin for their reactivity and
specificity (Fig. S4). The staining patterns of the antibodies listed in
Table S1 on Langerhans cells and dermal DCs of psoriatic skin
were consistent with data published in previous reports [19,33].
NALP-1 positive Langerhans cells are found in lesional
vitiligo skin
NALP-1 is part of the cytoplasmic complexes called inflamma-
somes that regulate the activation of caspases, which in turn
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forms [34]. Ying Jin and colleagues showed that variants of NALP-
1 may confer susceptibility to autoimmune and autoinflammatory
diseases that are associated with vitiligo [35,36]. Here, immuno-
histochemical staining of NALP-1 shows that the leading edge
vitiligo biopsies contained higher numbers of NALP-1 positive
epidermal cells compared to depigmented lesional and pigmented
nonlesional skin (Fig. 3A&B, p,0.05). We also performed double
immunofluorescence staining of NALP-1 and CD207/Langerin
on vitiligo biopsies (Figure S5). NALP-1 co-localized with CD207/
Langerin, the Langerhans cell marker, in the epidermal region of
leading edge vitiligo skin. NALP-1 bearing Langerhans cells
appear as orange dots in merged images (Fig. 3C), and more
noticeable colocalization of NALP-1 and CD207/Langerin were
found in leading edge vitiligo skin. Double immunofluorescence
staining of NALP-1 and HLA-DR also showed higher numbers of
activated HLA-DR
high Langerhans cells with positive NALP-1
expression in the epidermis of leading edge vitiligo skin (Fig. 3D).
Cytokines defining Th1 and Th17 but not Th2 activation
were increased in leading edge and lesional vitiligo skin
To compare the responses from different T helper cell
subpopulations in our vitiligo patients, we assessed the levels of
key cytokines: IFN-c, IL-4 and IL-17A, which are hallmarks of
Figure 1. T cell infiltration and loss of melanocytes in lesional and leading edge vitiligo skin. (A) Hematoxylin and eosin staining of non-
lesional, leading edge and depigmented vitiligo skin does not reveal any abnormality, but significant immune cell infiltrations were found in the
dermal regions of leading edge vitiligo biopsies. Bar=100 mm. (B) Immunohistochemical staining of Melan-A on non-lesional, leading edge and
depigmented vitiligo skin. The staining pattern of Melan-A is consistent with the degree of depigmentation in our vitiligo biopsies. Bar=100 mm. Bar
charts to the right of (B) is cell count of Melan-A positive cells of non-lesional, depigmented lesional and leading edge skin in biopsies of vitiligo
patients. Non-lesional vitiligo skin has significantly higher number of melanocytes than lesional (p,0.0027) and leading edge skin (p,0.0082).
Leading edge has significantly higher numbers of Melan-A positive cells than lesional vitiligo skin (C) Immunohistochemical staining of CD3+ T cells at
non-lesional, leading edge and depigmented lesional vitiligo skin. (D) Immunohistochemical staining of CD8+ T cells at non-lesional, leading edge
and depigmented lesional vitiligo skin. Bar=100 mm, applies to both C&D. T cell infiltrates are predominantly found at the dermal-epidermal
junctions in the leading edge vitiligo skin. Bar charts on the right to C&D provide the numbers from quantitative cell counting of CD3+ and CD8+ T
cells, respectively.
doi:10.1371/journal.pone.0018907.g001
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PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18907Figure 2. Characterization of Langerhans cells, dermal dendritic cells subpopulations in matched non-lesional, leading edge and
depigmented lesional skin. Quantification of each cell population per mm of skin appears on the right side of the micrograph image panels.
Representative immunohistochemical staining on non-lesional, leading edge and depigmented lesional skin of (A) CD207/Langerin: Langerhans cell
marker; (B) CD11c: myeloid dermal dendritic cell marker; (C) CD1c/BDCA-1: resident dermal dendritic cell marker; (D) HLA-DR: Activated Langerhans
cell and mature dermal DC marker. (E) DC-LAMP: mature DC marker. (F) Mouse IgG1, IgG2a, and IgG2b were applied at the same concentrations as
the matching primaries antibodies on leading edge vitiligo skin. Bar=100 mm, applies to 2A, B, C, D&E.
doi:10.1371/journal.pone.0018907.g002
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the levels of IL-1ß, an important cytokine for Th17 cell
development [37]. High expression levels of IFN-c were detected
in leading edge vitiligo skin, indicating Th1 cell activity (p,0.0705)
(Fig. 4A). In contrast, IL-4 levels were lowest in leading edge vitiligo
skin, when compared to non-lesional and lesional skin (Fig. 4B).
Th17 polarization of T helper cells in vitiligo was assessed by
qPCR analysis of mRNA levels of IL-17A. We found that IL-17A
expression in the leading edge was consistently higher than non-
lesional skin across different patient samples (p,0.0069) (Fig. 4C).
In addition, IL-1ß mRNA levels were highest in leading edge skin
biopsies, and the lowest expression level was found in non-lesional
samples (p,0.0313) (Fig. 4D).
Increased numbers of IL-17A+ cells and IL-17RA+ cells were
found at the upper dermis of leading edge vitiligo skin
To further verify our finding, we performed immunohistochemical
staining of IL-17A and IL-17RA across the three groups of vitiligo
biopsies. Leading edge vitiligo biopsies showed more IL-17A+ cells
and IL-17RA+ cells in the upper dermis compared to non-lesional
vitiligo skin (Fig. 5A&B). Double immunofluorescence staining of IL-
17A and IL-17RA was performed to identify receptor bound IL-17A.
We observed that 50–60% of IL-17RA positive cells are also IL-17A
positive in leading edge vitiligo biopsies. In comparison, only 20–30%
of IL-17RA positive cells are IL-17A positive in non-lesional and
lesional skin (Fig. 5C). In order to verify the specificity of our IL-17A
antibody, a blocking experiment using recombinant IL-17A was
performed on psoriasis lesional and non-lesional skin biopsies. After
pre-incubation with recombinant human IL-17A, no staining was
observed except for precipitates of antigen/antibody complexes (Fig.
S6). Psoriasis lesional skin was used as a positive control, since the
involvement of the IL-17/IL-23 axis in psoriasis has been well
characterized by several studies from this lab [19,22,33,38].
IL-17A producing T cells were found in vitiligo skin
Double immunofluorescence staining of IL-17A and CD3 in
leading edge vitiligo skin biopsies showed clear colocalization,
Figure 3. NALP-1 positive Langerhans cells are found in lesional vitiligo skin. Immunohistochemical staining of NALP-1 on vitiligo biopsies
and double staining of NALP-1 with CD207 and HLA-DR on lesional skin. (A) Immunohistochemical staining shows higher numbers of NALP-1 positive
inflammasomes in leading edge vitiligo skin biopsies when compared to normal skin from healthy patients. (B) Quantification of NALP-1 positive cells
per mm of skin (p,0.05) (C) NALP-1 colocalized with Langerin/CD207, a Langerhans cell marker, in lesional vitiligo skin. (D) NALP-1 colocalized with
HLA-DR, a marker for activated dendritic cells, in lesional vitiligo skin. In 3C&D, single-stained controls are above the merged image, white line
denotes dermal-epidermal junction. Fluorescent signals of NALP-1 appear as red, whereas Langerin and HLA-DR signals appear as green. Areas of
colocalization appear as orange. Bar=100 mm, applies to both A, C&D.
doi:10.1371/journal.pone.0018907.g003
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upper dermis (Fig. 6A). It is worthy to note that only less than 10%
of CD3+ cells were also IL-17A positive. IL-17A staining was also
seen on some CD3 negative cells, which may indicate NK cells
and other types of cells that produce IL-17A. It is important to
note that this staining pattern may actually reflect binding of IL-
17A to its receptors (IL-17RA, IL-17RC) on target cells of different
types. Therefore, we conducted co-staining of CD3+ and IL-
17RA, and no overlapping signals were observed on non-lesional,
leading edge or lesional biopsies (Fig. 6B). This result indicate that
IL-17A molecules, when they are receptor-bound, will most likely
not be found on CD3+ T cells, which explains why only a minority
of IL-17A staining co-localized with CD3 in Fig. 6A.
Discussion
Although vitiligo does not have any clear signs of clinical
inflammation, it has been established that most cases of non-
segmental vitiligo contain a microscopic inflammatory infiltrate
[2]. Infiltrating T cells have been found in peri-lesional vitiligo
skin, and circulating auto-antibodies and auto-reactive CD8+
cytotoxic T cells that recognize melanocyte antigens were detected
in the sera of a high proportion of vitiligo patients [39]. Th1
responses, as characterized by IFN-c, have been established in
vitiligo. T cells expanded from peri-lesional vitiligo skin show a
predominately type 1 cytokine profile (i.e. IFN-c and TNF-a) [12].
The treatment of vitiligo by using IFN-c inhibitors has also given
positive therapeutic responses [14].
A recent advance in our understanding of T cells in
autoimmune diseases has been the identification of the Th17
subset. Th17 cells are a distinct lineage of proinflammatory T
helper cells that are induced in the presence of IL-6/IL-21, TGF-ß
and IL-1ß and expanded under the stimulation of IL-23
[40,41,42]. Th17 cells have attracted wide interest as they have
been implicated in many inflammatory diseases that were
previously only linked to Th1 responses, including rheumatoid
arthritis, psoriasis, multiple sclerosis and Crohn’s disease
[43,44,45,46,47]. However, not all immune disorders or inflam-
matory diseases involve an active population of Th17 cells. In the
skin, for instance, psoriasis contains a prominent Th17 population
[19,22], but atopic dermatitis has a very minimal Th17
component [48]. In vitiligo, there has been very limited data on
whether and how Th17 cells participate in the disease pathogen-
esis. In a recent study, Basak and co-workers endeavored to
compare serum levels of IL-17 between healthy control and vitiligo
patient groups. They reported decreased serum TGF-ß levels in
vitiligo patients, but a quantitative comparison of serum IL-17
levels between the healthy control and vitiligo patient groups was
lacking [20]. In this study, we provided direct tissue evidence for
Th17 involvement in vitiligo, manifested by elevated IL-17A
mRNA levels and the presence of IL-17A+ T cells in the leading
edge of vitiligo biopsies.
Th1 and Th17 cells are often colocalized in autoimmune
environments such as psoriasis and multiple sclerosis [22,49]. It
has been proposed that Th1 and Th17 cells collaboratively
contribute to human autoimmune diseases. In a psoriasis study,
IFN-c has been shown to be a potent promoter of IL-17+ T cell
trafficking, induction and function in humans [50]. In a mouse
model, adoptively transferred Th17 polarized cells were able to
mediate destruction of advanced B16 melanoma and induce
vitiligo, but this therapeutic effect was critically dependent on IFN-
c production, whereas IL-17A and IL-23 depletion had little
Figure 4. qPCR analysis of Th1, Th2 and Th17 cytokines in non-lesional, leading edge and lesional skin. Gene expression levels of key
cytokines were adjusted against hARP across matching non-lesional, leading edge and lesional vitiligo skin pairs. (A) IFN-g and (B) IL-4 are hallmark
cytokines for Th1 and Th2 polarization, respectively. (C) IL-17A and (D) IL-1ß serve as hallmark cytokines for Th17 polarization; Two way paired t-tests
are performed for each data of gene expression data between non-lesional v.s. lesional, non-lesional v.s. leading-edge vitiligo skin. *p,0.05;
**, p,0.01.
doi:10.1371/journal.pone.0018907.g004
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there is an active Th17 component in addition to a Th1
component. The interplay between Th1 and Th17 populations
in vitiligo remains an intriguing avenue for future exploration.
Interleukin 17 can be produced by both CD4+ and CD8+ T
cells, as well as natural killer cells and natural killer T cells [43]. In
this study, we could not obtain shave biopsies from vitiligo patients
to phenotype IL-17A producing T cells by FACS, but we do
observe IL17A+ T cells in the dermal area of leading edge vitiligo
biopsies, as well as CD8+ cells infiltrating the basal layer of the
epidermis. We also see significant colocalization of IL-17A and IL-
17 receptor A in leading edge vitiligo skin. It has been reported
Figure 5. IL-17A and IL-17RA are found on vitiligo skin biopsies. Immunohistochemistry and immunofluorescence staining of IL-17A and IL-
17 receptor A on vitiligo skin biopsies. (A)&(B) In immunohistochemistry, IL-17A and IL-17RA showed strong staining on the upper dermis of leading
edge vitiligo skin when compared to non-lesional/pigmented vitiligo skin. (C) Double immunofluorescence staining of IL-17A and IL-17RA, areas of
orange shows receptor bound IL-17A molecules. 50–60% of IL-17RA positive cells are also IL-17A positive in leading edge vitiligo biopsies. In
comparison, only 20–30% of IL-17RA positive cells are IL-17A positive in non-lesional and lesional skin. Bar=100 mm, applies to 5A, B&C.
doi:10.1371/journal.pone.0018907.g005
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T lymphocytes specific for Melan-A [52], and melanoma patients
who went through Melan-A specific CD8+ T cell infusion
immunotherapy demonstrated melanocyte loss in regions of
normal skin [10].
IL-1ß is a key cytokine for the development of Th17 cells [37],
and it is activated in the inflammasomes formed by NOD-like
receptors (e.g. NALP-1, NALP-3) [53]. NALP1 is widely expressed
at low levels, but is present at a high level in immune cells,
particularly T cells and Langerhans cells [54], which may explain
the high IL-1ß levels in leading edge vitiligo biopsies. One of the
consequences of cytokine-orchestrated inflammation is apoptosis.
In addition to CD8+ cytotoxic T cell-mediated killing, melanocyte
loss in the leading edge of vitiligo skin may result in part from
increased synthesis and release of IL-1ß, and the accompanying
apoptotic microenvironment at the dermal-epidermal junctions.
Th17 cells are antigen restricted, and therefore the development
of autoimmune T cells would require antigen presentation by
dendritic cells. In theory, both Langerhans cells and dermal
dendritic cells could present antigens to T cells. Langerhans cells
appeared to be activated in leading edge and depigmented skin
based on their high HLA-DR expression and their location in the
epidermis could lead to direct contact with melanocyte processes
or cellular antigens. Alternatively, inflammatory CD11c+ DCs
that invade the epidermis might also capture melanocyte antigens.
As already recognized, inflammatory dermal dendritic cells may
stimulate Th17 cell proliferation through their production of IL-23
[19]. In vitro data suggest that IL-23 also provides survival signals
for already differentiated Th17 cells to strengthen the Th17
phenotype [55]. About half of CD11c+ dermal dendritic cells in
the skin are CD1c+, and the number of these increased
significantly in leading edge vitiligo biopsies. This is very different
from psoriasis where CD1c+ cells are not increased, but
inflammatory CD11c+ CD1c2 DCs are seen to expand in a
dramatic manner. Moreover, it has been discovered that CD11c+
dermal DCs express perforin and granzyme B as well as exhibit
cytotoxic activity against tumor cells [56]. It is possible that in
addition to presenting melanocyte-specific self-antigens, CD11c+
dermal DCs at the leading edge of vitiligo skin are directly
involved in the killing of melanocytes.
In summary, our findings established an activated Th17 axis in
vitiligo. The capture and presentation of melanocyte related
antigens by different sets of dendritic cells in the skin is an
interesting problem that needs to be addressed in future studies.
Our observation that Langerhans cells contain activated inflam-
masomes and that dermal CD11c+ DCs subsets are elevated could
indicate involvement of both epidermal and dermal DC
populations. This is a particularly interesting problem since
Langerhans cells and dermal DCs may have differing abilities to
activate Th1, Th2 and Th17 cell populations in humans [57].
Materials and Methods
Subjects and skin samples
This study was approved by The Rockefeller University
Institutional Review Board. Twenty patients with non-segmental
vitiligo were enrolled in the study. Informed written consents were
obtained from all patients before their participation. The study
was performed with strict adherence to the Declaration of Helsinki
Principles. The patients were of 18 years of age or older, and the
demographics of these patients are listed in Supplementary
Material Table S2. These patients had not undergone any
systemic therapies (including methotrexate, etretinate, PUVA or
cyclosporine) at least 4 weeks prior to entering the study. In
Figure 6. Detection of IL-17A producing T cells in vitiligo skin
biopsies. Double immunofluorescent staining of IL-17A/IL-17RA with
CD3 on leading edge vitiligo skin biopsies. (A) Co-staining of CD3 and
IL-17A reveals IL-17A+ T cells in vitiligo skin biopsies, but overlapping
signals were only found on a small number of CD3+ cells. IL-17A signals
on CD3 negative cells may reflect IL-17A molecules that are receptor
bound. (B) Co-staining of CD3 and IL-17RA does not show any
overlapping signals across the three groups of vitiligo biopsies, which
indicates that receptor bound IL-17A are not likely to colocalize with
CD3+ T cells. Bar=100 mm, applies to 6A&B.
doi:10.1371/journal.pone.0018907.g006
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and/or vitamin D analogs were allowed for these patients at least 4
weeks prior to entering the study. Pregnant or lactating women
were excluded from this study. For each volunteer, six-millimeter
punch biopsies were obtained of lesional (clinically depigmented),
leading edge (border between clinically depigmented and pig-
mented skin) and non-lesional skin (clinically pigmented). Subse-
quently, samples were frozen in OCT (Sakura, Torrance, CA,
U.S.A.) and kept at 280uC for immunohistochemistry.
Immunohistochemistry
Frozen sections were taken from all of the skin biopsies and were
stained with hematoxylin (Fisher Scientific, Pittsburgh, PA,
U.S.A.) and eosin (Shandon, Pittsburgh, PA, U.S.A.). For
immunohistochemistry, frozen sections were blocked with 10%
normal horse serum, and endogenous peroxidases were quenched
by incubation with diluted hydrogen peroxide (1:10 dilution of 3%
hydrogen peroxide). Sections were incubated overnight at 4uC
with primary mouse monoclonal antibodies. Biotin-labeled horse
anti-mouse antibodies were used for secondary binding, and
thereafter the signals were amplified with avidin-biotin complex (-
Vector Laboratories, Burlingame, CA, U.S.A.). Subsequently, the
sections were developed using chromogen 3-amino-9-ethylcarba-
zole (Sigma-Aldrich, St Louis, MO, U.S.A.).
Immunofluorescence staining
Vitiligo depigmented, pigmented and leading edge skin sections
(n=3) were fixed with acetone and blocked in 10% normal goat
serum (Vector Laboratories) for 30 minutes. Primary antibody was
incubated overnight at 4uC and amplified with the appropriate
secondary antibody: goat anti-mouse IgG1 conjugated with Alexa
Fluor 568 (Invitrogen/Molecular Probes, Eugene, OR) for
30 mins. For colocalization, sections were then costained over-
night with a second antibody: Langerin, HLA-DR, CD3, or IL-
17/IL-17RA, and amplified with the appropriate goat-anti mouse
IgG2b and IgG2a secondary antibody conjugated with Alexa
Flour 488, respectively. Images were acquired using appropriate
filters of a Zeiss Axioplan 2 widefield fluorescence microscope
fitted with a Plan Neofluar20 x60.7 numerical aperture lens and a
Hamamatsu Orca ER-cooled charge-coupled device camera,
controlled by METAVUE software (MDS Analytical Technolo-
gies, Downington, PA).
Antibodies
Table S1 in Supplementary Material lists the sources of
antibodies and their concentration for immunohistochemistry
and immuofluorescence stainings.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Skin samples were frozen in liquid nitrogen and RNA was
extracted from homogenized tissue using the RNeasy Mini Kit
(Qiagen, Valencia, CA, U.S.A.) and genes were amplified using
EZ PCR core reagents, primers and probes (Applied Biosystems,
Foster City, CA, U.S.A.). Sequences of primers and probes used in
this study were as follows: (IL-17A: Assay ID Hs00174383_m1,
IFN-c: Assay ID Hs00989291_m1, IL-1ß: Assay ID:
Hs00174097_m1, IL-4 Assay ID: Hs00174122_m1). RT-PCR
were performed on Applied Biosystems Prism 7700 Sequence
Detector using extracted RNA from vitiligo skin biopsies
according to the manufacturer’s directions and as previously
established [18,58,59]. The samples were amplified by using the
following thermal cycler conditions: 2 min at 50uC; 30 min at
60uC; 5 min at 95uC; 40 cycles of 15 sec at 95uC followed by
60 sec at 60uC. To make semi-quantitative measurements and
comparisons on relative gene expression, each gene expression
data were normalized against the house keeping gene hARP
(human acidic ribosomal protein), and analyzed with the Applied
Biosystems Sequence Detection Systems software version 2.3.
Cell counts
NIH Image program (http://rsb.info.nih.gov/nih-image/; NIH
Image version 6.1) allowed for manual counting at 206
magnification of total number of stained cells per mm of frozen
section.
Statistical Analysis
Nonparametric Freidman’s t-tests and two-tail paired t-tests
were used to compare cell counts per mm of paired lesional,
leading edge and non-lesional skin. Results were interpreted as
significant at P values less than 0.05, as trends and tending to
significance at P values less than 0.1. SEM were displayed in all the
bar graphs.
Supporting Information
Figure S1 CD3 and CD4 double stainings on vitiligo
biopsies. The majority of CD3+ cells are also CD4+ (.60%). In
the skin, CD32/CD4+ population will include dermal dendritic
cells; CD3+/CD42 cells are also dectected, indicating a mixed
CD4+ and CD8+ T cell infiltrate in vitiligo. (CD3 antibody: BD
Biosciences Cat No. 347340; CD4-FITC antibody: BD Bioscienc-
es 340133).
(TIF)
Figure S2 CD3 and CD8 double staining on vitiligo
biopsies. CD3+/CD8+ cells are found in non-lesional, leading
edge and lesional vitiligo skin, showing that CD3+ T cells contain
a mixture of CD4+ and CD8+ T cells.
(TIF)
Figure S3 CD83 staining on vitiligo biopsies. Scattered
CD83+ cells with dendritic morphology were found in the upper
dermis and epidermis of vitiligo biopsies, including non-lesional,
leading edge and depigmented. Some CD83+ cells are located in
the epidermis, consistent with LC maturation.
(TIF)
Figure S4 Positive controls for antibodies used in
identifying Langerhans cells and dermal DC subsets.
Before studying Langerhans cells and dermal DCs in vitiligo skin
biopsies, all antibodies were tested on psoriasis lesional and non-
lesional skin for their reactivity and specificity. Their staining
patterns on psoriatic skin were consistent with data published in
previous reports from this lab [32,33].
(TIF)
Figure S5 NALP-1 and Langerin double staining on
vitiligo biopsies. More NALP-1 positive cells are observed in
leading edge vitiligo biopsies. Almost 30% of Langerin+ cell are
also NALP-1 positive, whereas in NL, LS or normal skin (data not
shown), only 5–10% of Langerin+ cells were also NALP-1 positive.
(TIF)
Figure S6 IL-17A blocking experiment on psoriatic and
normal skin. (A) IL-17A staining on lesional, nonlesional
psoriatic skin and biopsies from normal healthy volunteers
(antibody was applied at a dilution of 1:500). (B) IL-17A antibody
was diluted at 1:500 and incubated at room temperature with
recombinant human IL-17A (R&D Systems Cat. No. 317-ILB) for
two hours at an Ab to Ag molar ratio of 1:10. The IL-17A anibody
Th17 Cells and Dermal DC in Vitiligo
PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e18907and rhIL-17A mixture was applied to three groups of skin biopsies,
and staining was performed in parallel with samples in panel A.
After blocking with rhIL-17A, no staining was seen across the
three groups of samples except for red precipitates of Ab/Ag
complexes. (C) IgG1 isotype control on lesional, non-lesional
psoriatic skin and normal skin.
(TIF)
Table S1 Sources of antibodies and their working
conditions.
(DOCX)
Table S2 Patient Demographics.
(DOCX)
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